AUDRA IBARRA: Open Payments
NPI 1700432622 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$513 in 25 payments from 14 companies in 2025. Trend: 2023 $828 · 2024 $437 · 2025 $513
Food & beverage: $513
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $95 |
| Novo Nordisk Inc | 3 | $73 |
| ABBVIE INC. | 3 | $68 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Exact Sciences Corporation | 2 | $39 |
| Nalu Medical, Inc. | 1 | $34 |
| Amgen Inc. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $23 |
| Boston Scientific Corporation | 1 | $21 |
| PFIZER INC. | 1 | $21 |
Products named: REXULTI, Ozempic, QULIPTA, AIRSUPRA, Nalu Neurostimulation System, REPATHA, Veozah, WaveWriter Alpha Prime 16.
Industry payments across AZ — which companies pay providers there.
